These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35058934)

  • 1. CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
    Hejazi M; Zhang C; Bennstein SB; Balz V; Reusing SB; Quadflieg M; Hoerster K; Heinrichs S; Hanenberg H; Oberbeck S; Nitsche M; Cramer S; Pfeifer R; Oberoi P; Rühl H; Oldenburg J; Brossart P; Horn PA; Babor F; Wels WS; Fischer JC; Möker N; Uhrberg M
    Front Immunol; 2021; 12():798087. PubMed ID: 35058934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities.
    Vargas-Inchaustegui DA; Demberg T; Robert-Guroff M
    Immunology; 2011 Nov; 134(3):326-40. PubMed ID: 21978002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL.
    Reusing SB; Vallera DA; Manser AR; Vatrin T; Bhatia S; Felices M; Miller JS; Uhrberg M; Babor F
    Cancer Immunol Immunother; 2021 Dec; 70(12):3701-3708. PubMed ID: 34398302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells.
    Handgretinger R; Schäfer HJ; Baur F; Frank D; Ottenlinger C; Bühring HJ; Niethammer D
    Immunol Lett; 1993 Aug; 37(2-3):223-8. PubMed ID: 7505004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
    Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
    Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-12 directs further maturation of ex vivo differentiated NK cells with improved therapeutic potential.
    Lehmann D; Spanholtz J; Sturtzel C; Tordoir M; Schlechta B; Groenewegen D; Hofer E
    PLoS One; 2014; 9(1):e87131. PubMed ID: 24498025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD56
    Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
    Front Immunol; 2019; 10():14. PubMed ID: 30761123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3.
    Scott AA; Head DR; Kopecky KJ; Appelbaum FR; Theil KS; Grever MR; Chen IM; Whittaker MH; Griffith BB; Licht JD
    Blood; 1994 Jul; 84(1):244-55. PubMed ID: 7517211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
    Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
    Front Immunol; 2021; 12():640672. PubMed ID: 34017328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering CAR-NK cells targeting CD33 with concomitant extracellular secretion of anti-CD16 antibody revealed superior antitumor effects toward myeloid leukemia.
    Zhang R; Liu Q; Zhou S; He H; Zhao M; Ma W
    Cancer Lett; 2023 Apr; 558():216103. PubMed ID: 36805460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ex vivo generated natural killer cells acquire typical natural killer receptors and display a cytotoxic gene expression profile similar to peripheral blood natural killer cells.
    Lehmann D; Spanholtz J; Osl M; Tordoir M; Lipnik K; Bilban M; Schlechta B; Dolstra H; Hofer E
    Stem Cells Dev; 2012 Nov; 21(16):2926-38. PubMed ID: 22571679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biology of human natural killer-cell subsets.
    Cooper MA; Fehniger TA; Caligiuri MA
    Trends Immunol; 2001 Nov; 22(11):633-40. PubMed ID: 11698225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human NK cells proliferate and die in vivo more rapidly than T cells in healthy young and elderly adults.
    Lutz CT; Karapetyan A; Al-Attar A; Shelton BJ; Holt KJ; Tucker JH; Presnell SR
    J Immunol; 2011 Apr; 186(8):4590-8. PubMed ID: 21402893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
    Marin V; Pizzitola I; Agostoni V; Attianese GM; Finney H; Lawson A; Pule M; Rousseau R; Biondi A; Biagi E
    Haematologica; 2010 Dec; 95(12):2144-52. PubMed ID: 20713459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells.
    Liu Y; Wang S; Schubert ML; Lauk A; Yao H; Blank MF; Cui C; Janssen M; Schmidt C; Göllner S; Kleist C; Zhou F; Rahfeld JU; Sauer T; Schmitt M; Müller-Tidow C
    Int J Cancer; 2022 Apr; 150(7):1141-1155. PubMed ID: 34766343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of natural killer and antibody-dependent cytolytic activities of the peripheral blood mononuclear cells of HIV-infected patients by recombinant IL-15.
    Loubeau M; Ahmad A; Toma E; Menezes J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Nov; 16(3):137-45. PubMed ID: 9390564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
    Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
    Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.
    Vallera DA; Felices M; McElmurry R; McCullar V; Zhou X; Schmohl JU; Zhang B; Lenvik AJ; Panoskaltsis-Mortari A; Verneris MR; Tolar J; Cooley S; Weisdorf DJ; Blazar BR; Miller JS
    Clin Cancer Res; 2016 Jul; 22(14):3440-50. PubMed ID: 26847056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.